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G protein-coupled receptors (GPCRs) are seven-transmembrane proteins that participate
in many aspects of the endocrine function and are important targets for drug development.
They transduce signals mainly, but not exclusively, via hetero-trimeric G proteins, leading to
a diversity of intracellular signaling cascades. Ligands binding at the hormone orthosteric
sites of receptors have been classified as agonists, antagonists, and/or inverse agonists
based on their ability to mainly modulate G protein signaling. Accumulating evidence also
indicates that such ligands, alone or in combination with other ones such as those acting
outside the orthosteric hormone binding sites (e.g., allosteric modulators), have the ability
to selectively engage subsets of signaling responses as compared to the natural endoge-
nous ligands. Such modes of functioning have been variously referred to as “functional
selectivity” or “ligand-biased signaling.” In this review, we provide an overview of the
current knowledge regarding GPCR-biased signaling and their functional regulation with a
focus on the evolving concept that receptor domains can also be targeted to allosterically
bias signaling, and discuss the usefulness of such modes of regulation for the design of
more efficient therapeutics.
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INTRODUCTION
G protein-coupled receptors (GPCRs) constitute the largest family
of cell-surface receptors and are involved in almost all physi-
ological and hormonal responses. Therefore, it is not surpris-
ing that they are the most targeted in drug discovery programs
(1). Their activation was first described by a classical two-state
model, where receptors exist in equilibrium between active (e.g., G
protein-coupled: the“on”state) and inactive states (e.g., G protein-
uncoupled: the“off”state), and where extracellular stimuli, such as
hormones, neurotransmitters, peptides, and amino acids, shift this
equilibrium from one state to the other. Based on this model, the
properties of ligands were classified as agonists, antagonists, and
inverse agonists, according to their ability to stabilize the “on” state
of receptors allowing the full activation of G proteins such as for
agonists, reducing the basal spontaneous coupling to G proteins
like in the case of the inverse agonists (e.g., maintaining recep-
tor in the “off” state), or inhibiting agonist competitively without
changing the equilibrium like for “neutral” antagonists. To explain
the biological and physiological responses triggered by these lig-
ands, this binary model also assumes that GPCRs preferentially
couple to one G protein subtype, and that either agonists, antag-
onists, or inverse agonists affect in a similar manner – according
to its respective class – the activation of such G protein. More-
over, if more than one G protein subtype binds to its cognate
receptor, each class of ligands would also affect it in a similar
manner. However, several new lines of evidence now support an
alternative multi-state model, where GPCRs can adopt multiple
conformations, including active, inactive, and other intermediate
ones. In such multi-state model, it is also inferred that ligands have
the propensity of stabilizing a unique conformation leading to a
specific signaling response, which may or may not always totally
mimic the one induced by a natural ligand of reference. These
ligands can stabilize a “hybrid” receptor conformation that mim-
ics the “on” conformation with respect to engaging one signaling
pathway, while at the same time mimicking the “off” conforma-
tion for another signaling pathway that is normally activated by
an agonist of reference. Such mode of ligand-mediated differen-
tial signaling is commonly referred to as “functional selectivity” or
“ligand-biased signaling,” and would in principle allow the activa-
tion of specific pathways and cell responses. It is now well-accepted
that many orthosteric ligands (OL) have the ability to bias signal-
ing between different G proteins and/or between G proteins and
β-arrestins that are involved in the desensitization, internalization,
and signaling of GPCRs. This latter mode of biased signaling has
already been extensively covered in many recent reviews (2–4), and
will not be furthermore expanded here.
Functional selectivity is not only limited to OLs, but is also
a property that has been described for other allosteric ligands
(AL)/effectors. These, which are also known as “allosteric mod-
ulators,” include ions, ligands, small and large molecules (e.g.,
antibodies) and/or protein complexes (e.g., receptor dimers and
receptor–effector complexes) that modulate hormone binding
and/or the intracellular coupling of receptors to their effectors,
and affect responses in different ways: they can have differential
cooperative effects – negative or positive ones – on the binding
of the OL, the “conduit” of the information of the ligand to the
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effector through the receptor, and the biasing of receptor signal-
ing. Moreover, an evolving concept also suggests that receptor
domains that participate in ligand and/or effector binding, and
in the “signaling conformations” of GPCRs, can also be targeted
to bias signaling. Here, we will expand on this concept of target-
ing receptors’ domains to allosterically regulate their signaling for
mainly class A and C GPCR, and review some of the potential
clinical and pre-clinical uses of biased AL.
BIASING GPCR SIGNALING BY ALLOSTERIC MODULATORS
Allosterism was first described with the hemoglobin, where the
binding of oxygen to a specific site increases the affinity of other
oxygen molecules to the remaining unoccupied sites (5). Over the
years, this concept has proven to be widely spread for various types
of proteins, and more recently for transmembrane receptors, such
as GPCRs. Interestingly, numerous endogenous allosteric mod-
ulators have been identified, and shown to play crucial roles in
keeping diverse biological functions mediated by this class of
receptors. To date, the best characterized GPCR allosteric mod-
ulator is the G protein itself, which binds receptors and stabilizes
their active conformation. Moreover, ions, such as Zn2+, Na+, and
Ca2+ are other examples of endogenous molecules that have been
shown to allosterically modulate GPCRs (6). In addition, other
types of endogenous modulators, such as the small tripeptide
Pro–Leu–Gly (PLG), also known as the melanocyte-stimulating
hormone release inhibiting factor (MIF-1) has also been shown
to act as an allosteric modulator on the D2 and the D4 dopamine
receptors. PLG increases the affinity of dopamine for its receptors
and the agonist-mediated inhibition of adenylyl cyclase (AC) (7).
Similarly to OLs that have the capacity to bias GPCR signaling, AL,
which bind to topographically distinct sites from the endogenous
ligands, can direct receptor signaling (Figure 1). They can either
exert positive, negative, or neutral effects on receptor signaling,
and these modulatory effects do not always parallel those seen on
the binding of OLs. Specifically, AL can influence the binding of
the orthosteric hormone to its receptor, which can be indepen-
dent from its impact on the signaling transduction promoted by
the OL itself. Their effects on receptor signaling have been mainly
divided into two categories: positive allosteric modulators (PAMs)
and negative allosteric modulators (NAMs). Many advantages are
known to be associated with the use of AL in terms of fine tun-
ing GPCR responses (8, 9). First, because AL bind sites on GPCRs
that are more diverse in nature than the orthosteric ones, greater
selectivity can be achieved with such ligands. Indeed, targeting
specific receptors belonging to the same family subtype has been
often challenging because of their highly conserved sequences and
structures within their orthosteric binding sites. For instance, class
C GPCRs, group II metabotropic glutamate receptors (mGluRs),
HOL ALH
Orthosteric Modulation Allosteric Modulation
H
Gα
β
γ β-arrestins Other
effectors
AL
FIGURE 1 | Directing signaling by orthosteric and allosteric GPCR
ligands, receptor complexes and domains. Signaling occurs
following the binding of endogenous hormones (H) to the orthosteric
site on G protein-coupled receptor (GPCR), which involves different
domains, mainly the transmembrane and extracellular ones. This leads
to the activation of multiple signaling pathways that are balanced
between the G proteins, β-arrestins, and/or other signaling effectors.
Ligand-directed signaling (i.e., biased signaling) can occur through the
binding of either orthosteric (OL) or allosteric (AL) ligands to the
receptor, which changes the balance of signaling between the effectors
as compared to a ligand of reference. Formation of receptors
complexes, such as dimers as well as reorientation of extra/intracellular
domains of receptors can also lead to conformational rearrangements
or be targeted for biased signaling.
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including mGluR2 and mGluR3, were selectively targeted by a
NAM, which only inhibited the glutamate-induced response of
group II receptors without exerting any effect on groups I and
III mGluRs (10). Second, the effect of allosteric modulators on
receptors is also saturable, since they are not competing with
endogenous ligands. In other words, when all allosteric sites are
occupied on receptors, no more effects are achieved. Third, most
allosteric modulators are known to exert their function only in the
presence of the endogenous ligand. Indeed, the AL will modulate
the receptors’ conformation and signaling only when the endoge-
nous hormone occupies its orthosteric site. However, some AL
have also been described to act as allosteric agonists and promote
functional effects in the absence of OLs and those are known as
ago-allosteric modulators. Such ligands have also been referred to
as “super-agonists,” because they can act synergistically with the
natural ligand. An example of ago-AL is the phenylacetamide 1 and
2, which act directly on the free fatty acid receptor 2 (FFA2) (11).
Another property of AL is also their ability to bias receptor
signaling. Such allosteric modulation has been mainly studied in
class A and C GPCRs. For example, a recent study characterized
a new compound, PDC113.824, acting as an allosteric modulator
on the class A GPCR, the prostaglandin F2α (FP) receptor. This
compound was shown to act as a PAM on the agonist-mediated
Gαq signaling pathway, while at the same time acting as a NAM on
the Gα12 signaling cascade (12). Another example of G protein-
dependent biased signaling is revealed by an autoantibody, which
targets a class C GPCR, the calcium-sensing receptor (CaSR)
and allosterically modulates the calcium-mediated potentiation
of Gαq signaling, while inhibiting the Gαi response (13). More-
over, the gadolinium (Gd3+), a known allosteric modulator of the
mGluR1α, was shown to act as a PAM on the agonist-mediated
Gαq and a NAM on the Gαs signaling pathway (14). Allosteric-
biased modulation on GPCRs is not only limited to G proteins vs.
G proteins signaling but can also occur between G proteins and
other signaling effectors, such as β-arrestins. For instance, the ATI-
2341 compound acting on the C–X–C chemokine receptor type 4
(CXCR4) was recently shown to display differential ago-allosteric
properties between G protein and β-arrestins signaling (15). ATI-
2341 preferentially promoted the coupling of CXCR4 to Gαi- over
Gα13-mediated signaling, but contrarily to the endogenous ligand,
did not induce β-arrestin recruitment to the receptor. On the other
hand, a study on the cannabinoid receptor 1 (CB1) showed that the
ORG27569 compound acted as an NAM on the agonist-mediated
Gαi signaling and a PAM on β-arrestin-dependent internalization
of CB1; and acted as an ago-allosteric modulator on both recep-
tor internalization and β-arrestin-dependent MAPK signaling (16,
17). These examples highlight the diversity of GPCR allosteric
modulators on both receptors and their ensuing signaling (e.g.,
PAM and NAM effects). However, defining how they differentially
direct downstream effectors and responses still remains an empir-
ical endeavor for most receptors. Moreover, because allosteric
modulators have the potential to differentially affect distinct effec-
tors and responses, much more work still remains to better survey
all the potential signaling pathways that can be affected, even the
ones that are not normally suspected to be activated by the receptor
studied.
TARGETING GPCR DOMAINS FOR ALLOSTERICALLY BIASING
RECEPTOR SIGNALING
Because different domains of GPCRs [e.g., intracellular loops
(ICL) and extracellular loops (ECL) and transmembrane domains
(TM)] are known to participate in ligand and/or effector recog-
nition and receptor dimerization, recent attention has also been
drawn to understand the role of these domains in receptor con-
formation and signaling. It is well-recognized that GPCRs can
form oligomers within which conformational rearrangements of
the receptors can impact signaling (Figure 1) (18, 19). An exam-
ple is the heterodimerization of the class A GPCRs chemokine
receptors, CXCR4 and CXCR7 (19). This study showed that, when
receptors are both in complex, agonist-mediated activation of Gαi
is impaired, whereas β-arrestin is constitutively recruited to the
dimer. Because other reviews have already covered the concept
of GPCR oligomers and its ensuing effects on directed signal-
ing, such topic will not be furthermore discussed here (20–22).
Of note, however, is a seminal study on the dimerization of the
β2-adrenergic receptor (β2AR), which used a peptide consisting
of residues 276–296 of the TM6 of the receptor (GIIMGTFTL-
CWLPFFIVNIVH), to prevent homodimerization, showed that
the agonist-mediated cAMP production could be inhibited; thus
suggesting that domains of GPCRs could be targeted to regu-
late receptors signaling in an allosteric fashion (23). In addition,
another study has also demonstrated that peptides derived from
TM of CXCR4 and CCR5 could be used as specific receptor
antagonists (24). Despite that TM are involved in ligand bind-
ing and receptor activation, targeting these regions with peptides
has proven to be difficult due to their hydrophobic nature.
Receptor ICLs are critical for GPCR signaling and can also be
targeted to modulate receptor’s responses (Table 1). For instance,
studies using mimics of ICL3 from many different GPCRs, such as
the adrenergic receptors α1B and α2A (α1BAR and α2AAR), as well
as the muscarinic acetylcholine receptors M1 and M2 (M1AChR
and M2AChR), have revealed the importance of this domain in
G protein coupling/activation (25). These peptides, which are
derived from regions of receptors’ loops were shown to disrupt
both Gαq and Gαi coupling to their cognate receptors and to
affect downstream signaling. Similar effects were also reported
for the angiotensin II type-2 receptor (AT2R) (26). Moreover,
because β-arrestins also bind ICLs, peptides derived from the ICL3
and ICL1 of receptors were also shown to block GPCR densen-
sitization (27). For example, a synthetic peptide corresponding
to the sequence of the full length of ICL3 of the luteinizing
hormone/choriogonadotropin receptor (LH/CGR) was shown to
reverse the agonist-mediated desensitization of AC activity when
incubated with membranes expressing LH/CGR by preventing the
interaction between β-arrestin and the receptor (28). Not only was
targeting receptor’s ICL shown to affect G protein and β-arrestin
binding, but it was also demonstrated to bias GPCR signaling
between these different pathways. Indeed, the ago-allosteric ATI-
2341 compound, which belongs to the pepducin family and that
is a short lipidated peptide of the ICL1 of the CXCR4, was shown
to promote biased signaling between G proteins and β-arrestins
(15). Consistent with the idea that intracellular domain of GPCRs
can be targeted to allosterically bias receptor signaling, a recent
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Table 1 | Role of GPCRs intracellular (ICL) and extracellular (ECL) domains in receptors function.
Domains Receptors Functions Reference
ICL C–X–C chemokine receptor type 4 A pepducin derived from ICL1 acts as allosteric agonist Quoyer et al. (15)
β2-adrenergic receptor Intrabodies targeting ICLs act as allosteric ligands Staus et al. (29)
C–C chemokine receptor type 3 Different residues of ICLs are important for agonist-induced
cellular responses (orthosteric)
Auger et al. (30)
Dopamine D2 and D3 receptors
(D2R–D3R)
Certain residues in ICL2 are important for the agonist-induced
translocation of arrestin3 (orthosteric)
Lan et al. (31)
α2-adrenergic receptor (α2AR) Certain residues in ICL3 are important for agonist-induced
signaling (orthosteric)
Small et al. (32)
Rhodopsin receptor Mimics of the ICL3 and ICL1 allosterically blocked arrestin binding Krupnick et al. (27)
Luteinizing hormone/
choriogonadotropin receptor (LHCGR)
Mimic of the ICL3 allosterically blocked arrestin-dependent
desensitization
Mukherjee et al. (28)
ECL V1α vasopressin receptor (V1αR) Residues of ECL2 are important for agonist binding and receptor
activation (orthosteric)
Conner et al. (33)
V2 vasopressin receptor (V2R) ECL1–2 mimics act as bias, allosteric ligands Rihakova et al. (34)
M3 muscarinic acetylcholine receptor
(m3AChR)
Residues of ECL2 are important for agonist-mediated signaling
(orthosteric)
Scarselli et al. (35)
Somatostatin receptor (SSTR) Anti-ECL2 antibodies act as selective allosteric agonists Leu and Nandi (36)
Prostaglandin F2α receptor (FP) ECL2 mimic acts as an allosteric modulator Peri et al. (37), Goupil
et al. (12)
C–C chemokine receptor type 5 (CCR5) Anti-ECL2 antibodies allosterically block HIV entry Blanpain et al. (38)
C–C chemokine receptor type 5 (CCR5) ECL2 mimic, acting as an allosteric modulator, blocks HIV entry Dogo-Isonagie et al.
(39), Thathiah et al. (40)
Parathyroid hormone 1 receptor
(PTH1R)
Different residues of ECL3 are important for PTH (1–34) binding
(orthosteric)
Lee et al. (41)
Adenosine A2B receptor (A2BR) Different residues of ECL1 are important for agonist-mediated
receptor activation (orthosteric)
Peeters et al. (42)
study on the β2AR, using different antibodies directed against its
intracellular domains, showed that the recruitment of β-arrestin
to the receptor and the activation of G proteins were differentially
affected (29). Targeting GPCR’s ICLs with peptide mimics has
proven efficient for regulating receptor signaling. However, such
approach can suffer from the impediment of having to modifying
the peptides (e.g., lipidation) for their cellular delivery. On the
other hand, the modification of peptides with lipids would favor
reaching higher plasma concentrations of peptide near its target,
the receptor, which would presumably increase their activity as
compared to a gene delivery approach.
The ECLs of GPCRs are also important in ligand binding
and receptor activation (Table 1). Using site-directed mutage-
nesis, residues in the ECL2 [Phe(189), Trp(206), Phe(209), and
Tyr(218)] of the V1α vasopressin receptor, which are highly con-
served amongst GPCRs, were shown to be critical for receptor acti-
vation (33). Another study focusing on the parathyroid hormone 1
receptor (PTHR) used a similar approach and identified residues
in the ECL3 (Trp-437 and Gln-440), which were important for
PTH (1–34) binding (41). Mutagenesis studies of the adenosine
A2B receptor have also implicated residues of the ECL1 in recep-
tor activation (42). The ECL2 was also shown to be important for
agonist binding and the activation of the M3 muscarinic acetyl-
choline receptor (M3AChR) (35), the C–C chemokine receptor
type 5 (CCR5) (43), the dopamine D2 receptor (D2R) (44), and
the complement factor 5α receptor (C5αR) (45). Other studies
have also explored the contribution of ECL2 in stabilizing recep-
tor conformations. For example, structural studies using NMR
spectroscopy reveal that the ECL2 forms a cap that stabilizes the
inactive conformation of the receptor and changes its orientation
upon receptor activation (46).
The ECL domains of GPCR can also be targeted to alloster-
ically modulate signaling. For instance, a recent study screened
potential small molecule for their action on the relaxin/insulin-
like family peptide receptor 1 (RXFP1), with the goal of finding
agonists. They identified compound 8, which displayed agonistic
effects on cellular responses such as cAMP production and cel-
lular impedance. Interestingly, using different RXFP1 constructs
and mutagenesis, they showed that the ECL3 of the receptor was
required for this effect, suggesting that the compound interacts
with an allosteric site within this ECL (47). Conversely, another
study showed that the agonist effects of the allosteric modulators
(phenylacetamide 1 and 2) on the FFA2 receptor were lost when
its ECL2 was replaced with one of the FFA3 subtype receptor (48).
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Moreover, antibodies against the ECL2 have been shown to mod-
ulate receptor activity. In the case of the somatostatin receptors
(SSTR), antibodies directed against their ECL2 have agonistic-like
properties, while having no effect on agonist binding to receptors.
SSTR2, SSTR3, and SSTR5 selective antibodies were also shown
to diminish cAMP production and decrease serotonin secretion
leading to a suppressed proliferation of neuroendocrine tumor
cells (36). Moreover, specific antibodies against the ECL2 of the
CCR5 were shown to block HIV entry in cells (38). Similarly, a
peptide mimic of the C-terminal portion of CCR5 was shown
to act as a NAM for HIV-1 entry (39). Not surprisingly, because
ECLs can adopt different conformations in GPCR, either at basal
state or upon receptor activation (46, 49), it can also be targeted
to allosterically bias receptor signaling. For instance, a study on
the vasopressin V2 receptor (V2R) using peptides correspond-
ing to a decapeptide of ECL1 (PPLLARAELA) or an octapeptide
of ECL2’s C-terminus (ALCRAVKY) showed physiological func-
tional selectivity on different vasopressin-mediated responses in
a non-competitive manner (34). Moreover, a peptide derived
from a sequence overlapping the N-terminus of ECL2 and the
TM4 of the prostaglandin F2α (FP) receptor, known as THG113
(ILGHRDYK), was able to block PGF2α-mediated contraction of
the myometrium in a non-competitive manner (37). Support-
ive for the allosteric regulation of the FP receptor signaling, is
the finding that a peptide mimic of THG113, the PDC113.824
compound, was also able to induce functional selectivity on G
protein signaling mediated by PGF2α (12). Also consistent with
the idea that the ECL2 can be targeted to direct receptor signaling
is the use of an allosteric modulator of the M2 and M4 muscarinic
acetylcholine receptors, LY2033298 compound, that was shown to
bias downstream signaling (50). Interestingly, a congener of the
LY2033298, the LY2119620 compound was later shown, through
co-crystallographic studies, to interact with residues of the ECL2,
and to allosterically alter M2 receptor active conformation (51).
The GPCRs’ ECLs represent promising targets for allosterically
modulating receptors, as they are presumably more accessible than
ICLs. In particular, ECL2 is a good target, because of its diversity
amongst GPCRs and because it is involved in the binding of OLs
and in the signaling of many receptors. However, much more needs
to be understood about how ECLs regulate ligand binding, recep-
tor conformation, and signaling, and how peptides derived from
these regions affect these functions.
THERAPEUTIC POTENTIALS OF ALLOSTERIC AND BIASED
SIGNALING
Recently, great attention has been devoted to functional selectiv-
ity as a new paradigm applicable for the development of better
therapeutic drugs with potentially fewer off-target and/or side
effects. An example is highlighted with the use of the biased agonist
pilocarpine, which selectively acts on the M1 muscarinic acetyl-
choline receptor and shows positive therapeutic effects in different
Alzheimer’s disease models. Specifically, pilocarpine biased Gαq-
mediated phospholipase C activation over the Gαs-mediated AC
stimulation, whereas the non-selective muscarinic agonist car-
bachol equally stimulated responses mediated by Gαs and Gαq
(52, 53). Moreover, biasing β-arrestin-dependent signaling has
also been shown to be potentially beneficial in heart diseases.
For example, TRV120027 (Sar–Arg–Val–Tyr–Ile–His–Pro-d-Ala-
OH), a peptide antagonist of the AT1R-dependent Gαq pathway
was recently shown to selectively induce β-arrestin signaling.
TRV120027 increases cardiomyocyte contractility in vitro, and
cardiac performance both in rats and dogs (54, 55), suggesting
that this orthosteric-biased ligand could be beneficial in acute
heart failure treatment (54). Another example is the biased lig-
and TRV130, which acts on the µ-opioid receptor and induces
cAMP inhibition through a Gαi-dependent mechanism without
inducing either β-arrestin recruitment or receptor internalization.
This biased agonist, which has similar potency and efficacy on Gαi
signaling as morphine, showed higher analgesic efficacy, lower res-
piratory suppression, and less gastrointestinal dysfunction when
compared to morphine (56).
Because AL can bias GPCR signaling, such modulators also
represent interesting opportunities for drug discovery (Table 2).
Moreover, greater subtype selectivity amongst receptors can be
achieved using AL, which may also improve therapeutic bene-
fits. For instance, the ADX10059 compound, a selective NAM for
the mGluR5, was shown to improve symptoms in patients suffer-
ing from gastro-esophageal reflux disease (GERD) (57, 58). On
the other hand, Reparixin (formerly Repertaxin), which acts as a
NAM on both chemokine receptors, CXCR1 and CXCR2, shows
promising therapeutic effects on the prevention of delayed graft
dysfunction after kidney transplantation and early stages of breast
cancer (59, 60). Research efforts focusing on targeting the ECL2
of GPCRs to allosterically modulate signaling, have also led to the
development of new drugs. Maraviroc, a peptide that was origi-
nally developed from a mimic of the ECL2 of CCR5 (discussed
in previous section), decreases the viral load in HIV-1 patients
(61). Because of the putative role of CCR5 in alloreactivity, Mar-
aviroc is also in phase II clinical trial for acute graft-versus-host
disease (GVHD). Moreover, the ECL2 mimic of the FP receptor,
PDC31 (derived from the THG113 peptide), which was shown
to inhibit preterm labor in different animal models, is now being
evaluated in a clinical phase II trial for primary dysmenorrhea (37,
62). Other examples of allosteric and biased drugs are currently
under pre-clinical investigation or in clinical trials (Table 2).
CONCLUSION AND PERSPECTIVES
The possibility of directing GPCR signaling with either OL or
AL has opened new opportunities for developing more selec-
tive/effective drugs; because, in principal, it would allow a bet-
ter control of the signaling pathway(s) involved in the under-
lying pathophysiology, hence limiting side effects that may be
engendered from the non-selective engagement of other GPCR
subtypes and/or from unwanted downstream signaling effec-
tors/responses. However, much more is needed to be under-
stood about directed signaling in order to develop better ther-
apeutics; especially about GPCR interaction with biased ligands
(orthosteric and allosteric ones) and their ensuing effects on
receptor conformation, and how such receptor–ligand complex
can convey signaling information in a selective manner. Chal-
lenges also include a better understanding of the role played by
GPCR domains such as the TMs, ECLs, and ICLs in the con-
formation of receptors and how different OL and AL ligands
affect these domains to stabilize subsets of conformations for
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Table 2 | Potential therapeutic usage of allosteric and biased GPCR signaling compounds/drugs.
Receptors Drugs Indications Reference
Calcium-sensing receptor (CaSR) Cinacalcet (marketed) Hyperparathyroidism Goodman et al. (63)
C–C chemokine receptor type 5 (CCR5) Maraviroc (marketed) AIDS/HIV Fätkenheuer et al. (61)
C–X–C chemokine receptor type 1/2
(CXCR1/2)
Reparixin Reperfusion injury in lung and kidney
transplantation
Bertini et al. (59), Zarbock et al. (64)
Prostaglandin F receptor (FP) PDC31 (THG113.3) Preterm labor and primary
dysmenorrheal
Olson and Ammann (62);
(http://clinicaltrials.gov/show/NCT01250587)
Metabotropic glutamate receptor 2
(mGluR2)
ADX71149 Schizophrenia Hashimoto et al. (65)
Metabotropic glutamate receptor 2/3
(mGluR2/3)
AZD8529 Schizophrenia (http://clinicaltrialsfeeds.org/clinical-
trials/show/NCT00985933)
Metabotropic glutamate receptor 5
(mGluR5)
AFQ056 Parkinson’s disease levodopa-induced
dyskinesia and fragile X syndrome
Berg et al. (66), Jacquemont et al. (67)
Dipraglurant
(ADX48621)
Parkinson’s disease levodopa-induced
dyskinesia and dystonia
Stocchi et al. (68); (http://www.
addextherapeutics.com/rd/pipeline/dipra-ir/)
ADX10059 Gastro-esophageal reflux Zerbib et al. (57); Stocchi et al. (68)
RO4917523 Depression and fragile X http://clinicaltrials.gov/ct2/show/study/
NCT01517698
Fenobam Fragile X Berry-Kravis et al. (69)
STX107 Fragile X and autism http://clinicaltrials.gov/show/NCT01325740
selective signaling. In particular, because allosteric compounds
may represent a promising new class of drugs, predicting their
sites of binding on GPCRs and modes of action – on the hor-
mone binding, conformation, and “conduit” of signaling (e.g.,
ago-agonist, PAM, or NAM) – becomes fundamental. Moreover,
because most GPCR can engage many downstream signaling path-
ways, which in many cases are cell-, tissue-, and/or context-specific,
it is essential to better define the entire “signaling repertoire”
for the hormones/drugs of reference and the putative-biased lig-
ands to be studied, particularly, in normal vs. pathological con-
ditions. Establishing such “signaling repertoire” becomes there-
fore essential in programs that aim at improving drug efficacy
or at repurposing drugs; hence, future research efforts should
be oriented toward the development of approaches for assess-
ing the full spectrum of signaling of the ligands of interest, in
different cell models, including those physiological and patho-
physiological relevant ones, and integrative analytical methods for
linking these “signaling signatures” to pre-clinical and/or existing
clinical data.
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